Cognitive Screening in Lung Cancer Patients

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Dec 6, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how lung cancer and its treatments might affect thinking and memory in patients. Specifically, it focuses on those with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) to see if they experience cognitive impairment, which means difficulties with thinking, remembering, or concentrating. The study will check participants' cognitive abilities during the first year after they join the trial using a detailed assessment.

To be eligible for this trial, participants need to be at least 18 years old and have a diagnosis of either NSCLC or SCLC at any stage. They should also be able to understand and read the local language. However, individuals aged 70 and older, those with certain brain problems, or anyone who has had other types of lung cancer before won’t be included. If you join the trial, you can expect to take part in assessments that will help researchers understand the impact of lung cancer and its treatment on cognitive functions. This study is currently recruiting participants, so there’s an opportunity for those who meet the criteria to contribute to important research that may benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
• • Age ≥ 18 years
• • Patients able to speak and read the local language(s) fluently
• • Acceptance and signature of informed consent
• Exclusion Criteria:
• • Age ≥ 70
• • Presence of brain metastases
• • Patients with concomitant neurological or psychiatric disorders.
• • Patients undergoing brain radiotherapy
• • Previous diagnosis of lung cancer